Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma

Kesavan, M.R.; Eyre, Toby A.; Collins, Graham P.

doi:10.1007/s11899-019-00518-8

Cited by 17 publications

(14 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite T-cell neoplasms being a heterogeneous disease group, many of our current chemotherapy approaches are rather uniformly adopted from those developed for aggressive B-cell lymphomas [ 272 , 273 , 274 , 275 , 276 ]. We have just recently begun to address certain entities more specifically.…”

Section: γδ T-cell Lymphoma/leukaemiamentioning

confidence: 99%

The Diverse Roles of γδ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma

Schönefeldt

Wais

Herling

et al. 2021

Cancers

View full text Add to dashboard Cite

γδ T cells are unique players in shaping immune responses, lying at the intersection between innate and adaptive immunity. Unlike conventional αβ T cells, γδ T cells largely populate non-lymphoid peripheral tissues, demonstrating tissue specificity, and they respond to ligands in an MHC-independent manner. γδ T cells display rapid activation and effector functions, with a capacity for cytotoxic anti-tumour responses and production of inflammatory cytokines such as IFN-γ or IL-17. Their rapid cytotoxic nature makes them attractive cells for use in anti-cancer immunotherapies. However, upon transformation, γδ T cells can give rise to highly aggressive lymphomas. These rare malignancies often display poor patient survival, and no curative therapies exist. In this review, we discuss the diverse roles of γδ T cells in immune surveillance and response, with a particular focus on cancer immunity. We summarise the intriguing dichotomy between pro- and anti-tumour functions of γδ T cells in solid and haematological cancers, highlighting the key subsets involved. Finally, we discuss potential drivers of γδ T-cell transformation, summarising the main γδ T-cell lymphoma/leukaemia entities, their clinical features, recent advances in mapping their molecular and genomic landscapes, current treatment strategies and potential future targeting options.

show abstract

Section: γδ T-cell Lymphoma/leukaemiamentioning

confidence: 99%

The Diverse Roles of γδ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma

Schönefeldt

Wais

Herling

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…More recently, the development of biological knowledge and the use of targeted drugs offer new therapeutic perspectives with chemo-free treatment strategies. [ 21 22 ]…”

Section: Morphologic Variantsmentioning

confidence: 99%

Non-Hodgkin's lymphoma: A review

Singh

Shaik

Negi

et al. 2020

J Family Med Prim Care

View full text Add to dashboard Cite

Lymphomas constitute the third most common neoplasm in head and neck region arising from the lymphoreticular system. Malignant lymphomas are divided into Hodgkin's disease and non-Hodgkin's lymphoma (NHL). NHL comprises approximately 5% of head and neck malignancies and displays a wide range of appearances comparable with Hodgkin's disease. Hodgkin's and non-Hodgkin's lymphomas are seen in the head and neck region, but extranodal disease, with or without lymph node involvement, is more common among NHL patients. Extranodal involvement includes the areas such as Waldeyer's ring (i.e., the tonsils, pharynx, and base of the tongue), salivary glands, orbit, paranasal sinuses, and thyroid glands. There are several classification systems for categorizing NHL out of which WHO classification for lymphoid neoplasms is mostly followed. This review describes the pathogenesis of NHL and explains some of the important NHL (Marginal zone B-cell Lymphoma, follicular lymphoma, mantle cell lymphoma).

show abstract

“…Rituximab-based chemoimmunotherapy is the preferred first-line treatment of diffuse large B cell lymphoma (DLBCL), and accumulating evidence demonstrated that dose attenuation does not compromise survival in the very elderly. Thus, R-CHOP (rituximab, cyclophosphamide, vincristine, prednisolone), especially R-CHOP-21 (every 21 days) remains a standard of care for most of these diseases, which can provide equivalent efficacy and a superior toxicity profile [ 46 ]. With the development of molecular biology, things were new.…”

Section: Discussionmentioning

confidence: 99%

Primary cutaneous diffuse large B-cell lymphoma after total knee arthroplasty: a case study and a systematic review of its cutaneous manifestations and treatment options

Chen¹,

Si²,

Gao³

et al. 2022

pdia

View full text Add to dashboard Cite

Introduction: Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL) after total knee arthroplasty (TKA) is rare. Aim: The literature that analyses the cutaneous manifestations of PCDLBCL and assesses the effect and the outcome of treatment is scarce. Material and methods: We described a case of PCDLBCL after TKA, whose cutaneous mass develops around surgical sites, mimicking a prosthetic joint infection. In addition, we conducted a systematic review of 29 reported cases with PCDLBCL. Primary endpoint for the review was main cutaneous manifestations of PCDLBCL. Secondary endpoint included treatment options of PCDLBCL and optimal therapeutic method. Results: We found that the main cutaneous manifestations include infiltrative cutaneous lesions such as macules, papules or nodules, some of them presented as ulcerations or formation of vesicles, subcutaneous nodules or both. The treatment options include excision, radiotherapy, chemotherapy, and even "watchful waiting" as spontaneous regression was noted in some cases. Systemic chemotherapy is the most frequent initial treatment approach chosen, of which rituximab is often combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy and patients who received systemic rituximab tend to have a better overall survival (OS) time than those who did not. Conclusions: PCDLBCL is a rare disease after TKA, however, an early recognition and distinguishing from infection is still needed. Patients with PCDLBCL may profit from rituximab-based chemotherapy, increasing the survival rate, despite the high relapse rate and limited OS time in some cases.

show abstract

Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma

Cited by 17 publications

References 100 publications

The Diverse Roles of γδ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma

The Diverse Roles of γδ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma

Non-Hodgkin's lymphoma: A review

Primary cutaneous diffuse large B-cell lymphoma after total knee arthroplasty: a case study and a systematic review of its cutaneous manifestations and treatment options

Contact Info

Product

Resources

About